Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selumetinib + sirolimus
- Development stage
- Phase 2
- Lead developer
- Sarcoma Alliance for Research through Collaboration
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Selumetinib + sirolimus** is an investigational oral combination therapy pairing the **MEK inhibitor selumetinib (AZD6244)**, which blocks the MAPK/ERK signaling pathway downstream of RAS/RAF, with the **mTOR inhibitor sirolimus (rapamycin)**, which inhibits the PI3K/AKT/mTOR pathway to suppress cell growth and proliferation. Developed for advanced sarcomas, particularly **unresectable or metastatic malignant peripheral nerve sheath tumors (MPNST)** associated with neurofibromatosis type 1 (NF1) or sporadic cases, the regimen targets synergistic pathway inhibition to overcome resistance seen with single agents. Administered as selumetinib 50 mg twice daily continuously and sirolimus 4 mg daily (with a 12 mg loading dose on cycle 1 day 1) in 28-day cycles, it is being evaluated in phase 2 trials like SARC031 for clinical benefit rate, progression-free survival, and toxicity profile, showing promise in NF1-MPNST where standard chemotherapies often fail.[1][4][7]
- Other names
- selumetinib and sirolimusAZD6244 + rapamycinselumetinib and sirolimus combination
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on selumetinib + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selumetinib + sirolimus.